http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-010641-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f9f32f7c860e9d4f852ee2c9f83d72b6 |
| filingDate | 1997-11-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2000-06-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-010641-A1 |
| titleOfInvention | A PHYSIOLOGICALLY ACCEPTABLE AQUEOUS SOLUTION AND ITS USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT |
| abstract | Physiologically acceptable aqueous solutions comprise multiple electrolytes, including: sodium ion, chloride ion, potassium ion, and calcium ion, and optionally magnesium ion. The solutions comprise a dynamic buffering system, where the term dynamic buffering system is used to refer to one or more reagents that work in combination to maintain the pH of the solution in a determined range in a live environment. The solution comprises a fundamental component of the dynamic buffering system which is a carboxylic acid, or a salt or ester thereof. Optionally, the dynamic buffering system may also include a source of bicarbonate, usually sodium bicarbonate (NaHCO3). The solution does not include a conventional biological buffer or buffer. By conventional buffer or buffer is meant a compound that, being in solution, in vitro, maintains the pH in a determined range. The solution also includes an on-line agent. The oncotic agent is made up of molecules whose size is sufficient to prevent their loss from circulation, by rapidly traversing the fenestrations of the capillary into the interstitial spaces of the tissues of the body. Compounds that are used as oncotic agents can be natural or synthetic, and are typically polymeric compounds that have an average molecular weight of at least about 40,000, usually at least about 100,000, and more frequently about 200,000, where the oncotic agents whose molecular weight is 300,000 or more. The solution can be used to manufacture a drug that is useful as a substitute for plasma, when it is introduced into the circulatory system of the host. |
| priorityDate | 1997-11-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 22.